LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 95

Search options

  1. Book: ADHD

    Hammerness, Paul Graves

    (Biographies of disease)

    2009  

    Author's details Paul Graves Hammerness
    Series title Biographies of disease
    Keywords Attention Deficit Disorder with Hyperactivity ; Child ; Adolescent ; Attention-deficit hyperactivity disorder
    Subject code 618.928589
    Language English
    Size 147 S. : Ill., 24cm
    Publisher Greenwood
    Publishing place Westport, Conn. u.a.
    Publishing country United States
    Document type Book
    Note Includes bibliographical references and index
    HBZ-ID HT015836868
    ISBN 0-313-34302-0 ; 978-0-313-34302-5
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Article ; Online: Cardiovascular Considerations for Stimulant Class Medications.

    Hammerness, Paul / Berger, Amy / Angelini, Michael C / Wilens, Timothy E

    Child and adolescent psychiatric clinics of North America

    2022  Volume 31, Issue 3, Page(s) 437–448

    Abstract: The cardiovascular (CV) impact of stimulants has been examined for decades, with investigations ranging from small sample targeted studies of heart rate (HR) and blood pressure (BP), to large scale epidemiologic investigations. The preponderance of ... ...

    Abstract The cardiovascular (CV) impact of stimulants has been examined for decades, with investigations ranging from small sample targeted studies of heart rate (HR) and blood pressure (BP), to large scale epidemiologic investigations. The preponderance of evidence is reassuring, albeit generally based on healthy samples using variable methodology, excluding those at theoretic high risk (eg, comorbid cardiac illness). Screening for theoretically vulnerable patients are recommended, as well as monitoring for CV symptoms and BP/HR, with shared inquiry/further evaluation if concerned. Future investigations to support the identification of risk are needed, while attention to stimulant-associated CV risk is an opportunity for clinicians to engage in general CV risk identification and intervention.
    MeSH term(s) Attention Deficit Disorder with Hyperactivity/drug therapy ; Attention Deficit Disorder with Hyperactivity/epidemiology ; Blood Pressure ; Central Nervous System Stimulants/adverse effects ; Heart Rate ; Humans
    Chemical Substances Central Nervous System Stimulants
    Language English
    Publishing date 2022-05-11
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1313996-4
    ISSN 1558-0490 ; 1056-4993
    ISSN (online) 1558-0490
    ISSN 1056-4993
    DOI 10.1016/j.chc.2022.02.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Effectiveness of collaborative tele-mental health care for children with attention deficit hyperactivity disorder in United Arab Emirates.

    Albanna, Ammar / Soubra, Karina / Alhashmi, Deena / Alloub, Zainab / AlOlama, Fatma / Hammerness, Paul / Lakshmanan, Jeyaseelan / Hechtman, Lily / Hamoda, Hesham

    Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit

    2023  Volume 29, Issue 9, Page(s) 742–748

    Abstract: Background: Attention deficit hyperactivity disorder is a common neurodevelopmental disorder. Accessing services for this disorder is a worldwide challenge and requires innovative interventions.: Aims: We aimed to investigate the effectiveness of ... ...

    Abstract Background: Attention deficit hyperactivity disorder is a common neurodevelopmental disorder. Accessing services for this disorder is a worldwide challenge and requires innovative interventions.
    Aims: We aimed to investigate the effectiveness of tele-collaborative care for attention deficit hyperactivity disorder in primary health care centres in Dubai.
    Methods: Six trained physicians started collaborative care clinics across Dubai. Eligible children aged 6-12 years attending primary health care centres with attention deficit hyperactivity disorder were randomly selected to receive telehealth collaborative care, or standard treatment. Baseline assessments were conducted using the Vanderbilt Behavioral Assessment Scale, the Columbia Impairment Scale, the Childhood Behavior Checklist, and the Strength and Difficulties Questionnaire. Waiting times and clinical and functional outcomes were measured in both groups and compared. Continuous variables were presented as means and standard deviations, categorical variables such as sex were presented as numbers and percentages, and continuous outcome variables were compared using the Student t-test.
    Results: Among the referred children (n = 112), 11 boys and 6 girls met the eligibility criteria (mean age 7.8 years). The dropout rate at 6 months in the control group was 80%, compared with 50% in the intervention group. The mean waiting time was significantly shorter in the intervention group (1.3 weeks) than the control group (7.1 weeks); P = 0.026. The mean difference in the Childhood Behavior Checklist total score over time was significantly higher in the intervention group (P = 0.042), but the mean difference in the Vanderbilt scale was not significant.
    Conclusion: Tele-collaborative care for children with attention deficit hyperactivity disorder within primary health care is feasible.
    Language English
    Publishing date 2023-09-09
    Publishing country Egypt
    Document type Journal Article
    ZDB-ID 1291071-5
    ISSN 1687-1634 ; 1020-3397
    ISSN (online) 1687-1634
    ISSN 1020-3397
    DOI 10.26719/emhj.23.076
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: New stimulant formulations for pediatric attention-deficit/hyperactivity disorder: a case-based approach for the primary care provider.

    Partain, Paige I / White, Jacob / Hammerness, Paul

    Current opinion in pediatrics

    2019  Volume 31, Issue 1, Page(s) 166–174

    Abstract: Purpose of review: To provide an up-to-date clinical review of U.S. Food and Drug Administration (FDA)-approved stimulant medications for attention-deficit/hyperactivity disorder (ADHD), including a framework for individualized treatment by primary care ...

    Abstract Purpose of review: To provide an up-to-date clinical review of U.S. Food and Drug Administration (FDA)-approved stimulant medications for attention-deficit/hyperactivity disorder (ADHD), including a framework for individualized treatment by primary care pediatric providers.
    Recent findings: Stimulant medications are first-line agents for pediatric ADHD. Since 2012, 11 novel stimulant medications have been approved by the FDA for the treatment of ADHD. Because of an expanded formulary of available methylphenidate-based and amphetamine-based stimulants, primary care providers may be unfamiliar with some novel medications outside a select formulary.
    Summary: The current broad formulary of methylphenidate-based and amphetamine-based stimulants provides primary care clinicians with a greater opportunity for personalized medicine within the patient-centered medical home. Through a systematic review of prior relevant medication trials, a consideration of daily symptom burden and thoughtful pragmatics, primary care providers can offer a more precise, customized stimulant treatment.
    MeSH term(s) Attention Deficit Disorder with Hyperactivity/drug therapy ; Central Nervous System Stimulants/therapeutic use ; Child ; Humans ; Methylphenidate/therapeutic use ; Primary Health Care
    Chemical Substances Central Nervous System Stimulants ; Methylphenidate (207ZZ9QZ49)
    Language English
    Publishing date 2019-02-01
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1049374-8
    ISSN 1531-698X ; 1040-8703
    ISSN (online) 1531-698X
    ISSN 1040-8703
    DOI 10.1097/MOP.0000000000000718
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Assessment and Treatment of a Young Adult with Congenital Heart Disease and ADHD.

    Hammerness, Paul G / Cassidy, Adam R / Potts, Heather / Richardson, Alanna / Fogler, Jason / Daly, Kevin P / Augustyn, Marilyn

    Journal of developmental and behavioral pediatrics : JDBP

    2021  Volume 42, Issue 4, Page(s) 340–342

    Abstract: Case: Phillip is a young man born with hypoplastic left heart syndrome referred to your practice for a range of mental health concerns. He underwent palliation to an extracardiac Fontan in infancy and experienced multiple complications over the next ... ...

    Abstract Case: Phillip is a young man born with hypoplastic left heart syndrome referred to your practice for a range of mental health concerns. He underwent palliation to an extracardiac Fontan in infancy and experienced multiple complications over the next decade including valvular regurgitation and arrhythmias necessitating a pacemaker. Phillip continued to have systolic heart failure with New York Heart Association class II symptoms, managed with 4 medications and anticoagulation.Despite this complex history, Phillip had intact cognitive abilities, achieved typical milestones, and performed well academically in secondary school. His first year of college proved to be more challenging, and Phillip presented to the outpatient psychiatry service with an acute depressive episode. His family history included depression, without known attention-deficit/hyperactivity disorder (ADHD). Treatment, including a selective serotonin reuptake inhibitor, cognitive behavioral therapy, and family support, led to near resolution of his symptoms of depression.In subsequent appointments, Phillip described a long history of inattention and disorganization with onset in childhood. This contributed to the decision to leave college, despite remission of symptoms of depression. Phillip was unable to study for any extended period without "perfect conditions," described as the absence of potential distractions except for background music. Despite attempts to maintain "perfect conditions," Phillip was often off task and "hyperfocusing" on irrelevant topics. Phillip struggled with planning and time management and would misplace items daily. Moreover, although the importance of self-care was well understood, Phillip often forgot to take his cardiac medication or to exercise, and he admitted to inconsistent sleep habits because of losing track of time.Based on a comprehensive psychiatric evaluation including retrospective report from a parent, Phillip was diagnosed with ADHD, coexisting with major depressive disorder, in remission. Significant ADHD symptoms were documented by interview, self-report, and administration of an abbreviated neuropsychological battery.Considering concerns regarding use of stimulants in a patient with congenital heart disease, including death, stroke, and myocardial infarction,1,2 how would you assess the risks-benefits of use of stimulants with Phillip?
    References: 1. Wilens TE, Prince JB, Spencer TJ, et al. Stimulants and sudden death: what is a physician to do? Pediatrics. 2006;118:1215-1219.2. Zito JM, Burcu M. Stimulants and pediatric cardiovascular risk. J Child Adolesc Psychopharmacol. 2017;27:538-545.
    MeSH term(s) Attention Deficit Disorder with Hyperactivity/drug therapy ; Central Nervous System Stimulants/therapeutic use ; Child ; Depressive Disorder, Major ; Heart Defects, Congenital/complications ; Heart Defects, Congenital/therapy ; Humans ; Male ; Retrospective Studies ; Young Adult
    Chemical Substances Central Nervous System Stimulants
    Language English
    Publishing date 2021-02-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 603379-9
    ISSN 1536-7312 ; 0196-206X
    ISSN (online) 1536-7312
    ISSN 0196-206X
    DOI 10.1097/DBP.0000000000000961
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.

    Chan, Eugenia / Fogler, Jason M / Hammerness, Paul G

    JAMA

    2016  Volume 315, Issue 18, Page(s) 1997–2008

    Abstract: Importance: Although attention-deficit/hyperactivity disorder (ADHD) is highly prevalent in adolescents and often persists into adulthood, most studies about treatment were performed in children. Less is known about ADHD treatment in adolescents.: ... ...

    Abstract Importance: Although attention-deficit/hyperactivity disorder (ADHD) is highly prevalent in adolescents and often persists into adulthood, most studies about treatment were performed in children. Less is known about ADHD treatment in adolescents.
    Objective: To review the evidence for pharmacological and psychosocial treatment of ADHD in adolescents.
    Evidence review: The databases of CINAHL Plus, MEDLINE, PsycINFO, ERIC, and the Cochrane Database of Systematic Reviews were searched for articles published between January 1, 1999, and January 31, 2016, on ADHD treatment in adolescents. Additional studies were identified by hand-searching reference lists of retrieved articles. Study quality was rated using McMaster University Effective Public Health Practice Project criteria. The evidence level for treatment recommendations was based on Oxford Centre for Evidence-Based Medicine criteria.
    Findings: Sixteen randomized clinical trials and 1 meta-analysis, involving 2668 participants, of pharmacological and psychosocial treatments for ADHD in adolescents aged 12 years to 18 years were included. Evidence of efficacy was stronger for the extended-release methylphenidate and amphetamine class stimulant medications (level 1B based on Oxford Centre for Evidence-Based Medicine criteria) and atomoxetine than for the extended-release α2-adrenergic agonists guanfacine or clonidine (no studies). For the primary efficacy measure of total symptom score on the ADHD Rating Scale (score range, 0 [least symptomatic] to 54 [most symptomatic]), both stimulant and nonstimulant medications led to clinically significant reductions of 14.93 to 24.60 absolute points. The psychosocial treatments combining behavioral, cognitive behavioral, and skills training techniques demonstrated small- to medium-sized improvements (range for mean SD difference in Cohen d, 0.30-0.69) for parent-rated ADHD symptoms, co-occurring emotional or behavioral symptoms, and interpersonal functioning. Psychosocial treatments were associated with more robust (Cohen d range, 0.51-5.15) improvements in academic and organizational skills, such as homework completion and planner use.
    Conclusions and relevance: Evidence supports the use of extended-release methylphenidate and amphetamine formulations, atomoxetine, and extended-release guanfacine to improve symptoms of ADHD in adolescents. Psychosocial treatments incorporating behavior contingency management, motivational enhancement, and academic, organizational, and social skills training techniques were associated with inconsistent effects on ADHD symptoms and greater benefit for academic and organizational skills. Additional treatment studies in adolescents, including combined pharmacological and psychosocial treatments, are needed.
    MeSH term(s) Adolescent ; Adrenergic alpha-2 Receptor Agonists/therapeutic use ; Amphetamines/therapeutic use ; Atomoxetine Hydrochloride/therapeutic use ; Attention Deficit Disorder with Hyperactivity/psychology ; Attention Deficit Disorder with Hyperactivity/therapy ; Central Nervous System Stimulants/therapeutic use ; Clonidine/therapeutic use ; Delayed-Action Preparations/therapeutic use ; Guanfacine/therapeutic use ; Humans ; Methylphenidate/therapeutic use ; Motivation ; Psychotherapy/methods ; Randomized Controlled Trials as Topic ; Social Skills
    Chemical Substances Adrenergic alpha-2 Receptor Agonists ; Amphetamines ; Central Nervous System Stimulants ; Delayed-Action Preparations ; Methylphenidate (207ZZ9QZ49) ; Guanfacine (30OMY4G3MK) ; Atomoxetine Hydrochloride (57WVB6I2W0) ; Clonidine (MN3L5RMN02)
    Language English
    Publishing date 2016-05-10
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2016.5453
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Corrected QT interval changes with atypical antipsychotics.

    Munshi, Kaizad / Alexander, Mark E / Hammerness, Paul

    Journal of the American Academy of Child and Adolescent Psychiatry

    2015  Volume 54, Issue 1, Page(s) 9–10

    MeSH term(s) Antipsychotic Agents/therapeutic use ; Humans ; Risk Factors
    Chemical Substances Antipsychotic Agents
    Language English
    Publishing date 2015-01
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 392535-3
    ISSN 1527-5418 ; 0890-8567
    ISSN (online) 1527-5418
    ISSN 0890-8567
    DOI 10.1016/j.jaac.2014.10.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Do Stimulants Reduce the Risk for Alcohol and Substance Use in Youth With ADHD? A Secondary Analysis of a Prospective, 24-Month Open-Label Study of Osmotic-Release Methylphenidate.

    Hammerness, Paul / Petty, Carter / Faraone, Stephen V / Biederman, Joseph

    Journal of attention disorders

    2017  Volume 21, Issue 1, Page(s) 71–77

    Abstract: Objective: The purpose of this study was to examine the impact of stimulant treatment on risk for alcohol and illicit drug use in adolescents with ADHD.: Method: Analysis of data derived from a prospective open-label treatment study of adolescent ... ...

    Abstract Objective: The purpose of this study was to examine the impact of stimulant treatment on risk for alcohol and illicit drug use in adolescents with ADHD.
    Method: Analysis of data derived from a prospective open-label treatment study of adolescent ADHD ( n = 115, 76% male), and a historical, naturalistic sample of ADHD ( n = 44, 68% male) and non-ADHD youth ( n = 52, 73% male) of similar age and sex. Treatment consisted of extended-release methylphenidate in the clinical trial or naturalistic stimulant treatment. Self-report of alcohol and drug use was derived from a modified version of the Drug Use Screening Inventory.
    Results: Rates of alcohol and drug use in the past year were significantly lower in the clinical trial compared with untreated and treated naturalistic ADHD comparators, and similar to rates in non-ADHD comparators.
    Conclusion: Well-monitored stimulant treatment may reduce the risk for alcohol and substance use in adolescent ADHD.
    MeSH term(s) Adolescent ; Attention Deficit Disorder with Hyperactivity/diagnosis ; Attention Deficit Disorder with Hyperactivity/drug therapy ; Central Nervous System Stimulants/administration & dosage ; Child ; Drug Administration Schedule ; Female ; Humans ; Male ; Methylphenidate/administration & dosage ; Osmosis ; Prospective Studies ; Risk Factors ; Substance-Related Disorders/complications ; Substance-Related Disorders/prevention & control ; Underage Drinking/prevention & control
    Chemical Substances Central Nervous System Stimulants ; Methylphenidate (207ZZ9QZ49)
    Language English
    Publishing date 2017
    Publishing country United States
    Document type Clinical Trial ; Journal Article
    ZDB-ID 2004350-8
    ISSN 1557-1246 ; 1087-0547
    ISSN (online) 1557-1246
    ISSN 1087-0547
    DOI 10.1177/1087054712468051
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: A Case of Emotional Trauma in the Setting of Neurodevelopmental Disability.

    Hauptman, Aaron J / Acar, Diler / Hammerness, Paul / Fogler, Jason M / Stafford, Diane

    Harvard review of psychiatry

    2018  Volume 26, Issue 6, Page(s) 384–391

    MeSH term(s) Adjustment Disorders/diagnosis ; Adolescent ; Humans ; Intellectual Disability/diagnosis ; Male ; Prader-Willi Syndrome/diagnosis ; Stress Disorders, Post-Traumatic/diagnosis
    Language English
    Publishing date 2018-11-08
    Publishing country United States
    Document type Case Reports ; Clinical Conference ; Journal Article
    ZDB-ID 1174775-4
    ISSN 1465-7309 ; 1067-3229
    ISSN (online) 1465-7309
    ISSN 1067-3229
    DOI 10.1097/HRP.0000000000000209
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Book: ADHD

    Hammerness, Paul Graves

    (Biographies of disease)

    2009  

    Author's details Paul Graves Hammerness
    Series title Biographies of disease
    MeSH term(s) Attention Deficit Disorder with Hyperactivity ; Child ; Adolescent
    Language English
    Size 147 p. :, ill. ;, 25 cm.
    Publisher Greenwood Press
    Publishing place Westport, Conn
    Document type Book
    ISBN 9780313343025 ; 0313343020
    Database Catalogue of the US National Library of Medicine (NLM)

    More links

    Kategorien

To top